Alvotech Lauds Development, Manufacturing Platform As Ustekinumab Wins US Approval
Commercial Partner Teva Eyes Launch In February 2025 For Rival To $7bn Blockbuster
Alvotech’s high confidence for FDA approval for its Stelara biosimilar has been justified, as the Icelandic firm announced only the second US approval for a rival to J&J’s Stelara powerhouse brand, ahead of market formation in 2025.
